Connective Portfolio Management LLC Boosts Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Connective Portfolio Management LLC lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 40.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,000 shares of the medical research company’s stock after buying an additional 2,600 shares during the quarter. Natera comprises 1.3% of Connective Portfolio Management LLC’s investment portfolio, making the stock its 19th biggest position. Connective Portfolio Management LLC’s holdings in Natera were worth $1,143,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Itau Unibanco Holding S.A. bought a new position in Natera in the 2nd quarter valued at $28,000. Quarry LP boosted its stake in Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after buying an additional 190 shares during the period. GAMMA Investing LLC grew its position in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after buying an additional 108 shares in the last quarter. YHB Investment Advisors Inc. bought a new position in Natera in the 1st quarter worth about $36,000. Finally, Tobam purchased a new stake in shares of Natera in the 2nd quarter valued at about $74,000. 99.90% of the stock is owned by institutional investors.

Natera Trading Down 0.2 %

NASDAQ:NTRA traded down $0.30 during mid-day trading on Wednesday, reaching $131.63. 43,191 shares of the company’s stock traded hands, compared to its average volume of 1,347,429. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $133.54. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The company has a 50 day moving average price of $119.52 and a 200-day moving average price of $108.62. The firm has a market capitalization of $16.16 billion, a price-to-earnings ratio of -42.29 and a beta of 1.53.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. The company had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm’s revenue for the quarter was up 58.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.97) earnings per share. On average, sell-side analysts predict that Natera, Inc. will post -1.96 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on NTRA shares. Robert W. Baird raised their target price on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Stephens reissued an “overweight” rating and issued a $125.00 target price on shares of Natera in a research note on Friday, August 9th. BTIG Research raised their price target on Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Piper Sandler reiterated an “overweight” rating and issued a $150.00 price objective on shares of Natera in a report on Friday, September 13th. Finally, TD Cowen upped their target price on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus price target of $120.07.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 5,496 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $111.66, for a total value of $613,683.36. Following the completion of the sale, the chief executive officer now directly owns 207,855 shares in the company, valued at $23,209,089.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In other Natera news, insider Daniel Rabinowitz sold 1,057 shares of the business’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $102.77, for a total value of $108,627.89. Following the sale, the insider now directly owns 206,400 shares of the company’s stock, valued at approximately $21,211,728. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 5,496 shares of the firm’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $111.66, for a total value of $613,683.36. Following the transaction, the chief executive officer now owns 207,855 shares of the company’s stock, valued at $23,209,089.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 51,738 shares of company stock worth $6,040,584 over the last 90 days. 7.60% of the stock is owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.